ArticleRespiratory research2025
Impact of combined endoscopic therapy on progression-free survival in patients with primary tracheal cancers: a multivariate-adjusted retrospective cohort study.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to assess the benefits and safety of combining endoscopic interventional therapy with surgery in patients with primary tracheal cancer. PATIENTS AND
methodsThis single-center retrospective cohort study included 39 patients with primary tracheal malignancies treated between January 2015 and August 2020. They were divided into a surgery-only group (Group A, n = 21) and a surgery plus endoscopic therapy group (Group B, n = 18). The primary endpoints were progression-free survival (PFS) and 5-year survival rate. Participants were followed up every three months, which included CT scans and assessments of treatment efficacy. Multivariate Cox regression models were employed to adjust for potential confounding factors.
resultsAdenoid cystic carcinoma (ACC) was the predominant histology in the entire cohort (64.1%). Median PFS was significantly longer in the combined therapy group compared to the surgery-only group (55.05 months vs. 35.8 months, P = 0.0276). In the subgroup analysis for ACC, the combination therapy group consistently showed a trend toward superior outcomes, though the differences did not reach statistical significance. The 5-year survival rates were 66.7% and 57.1% in the combined therapy and surgery-only groups, respectively. All treatment-related adverse events were mild to moderate, with no serious adverse events reported.
conclusionSurgery combined with endoscopic intervention significantly improves PFS in patients with primary tracheal carcinoma and shows a trend toward superior 5-year survival rate without increasing severe toxicity. This represents a safe and effective treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.